Fahar Merchant
Chief Executive Officer presso MEDICENNA THERAPEUTICS CORP.
Patrimonio netto: 7 M $ in data 31/03/2024
Posizioni attive di Fahar Merchant
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| MEDICENNA THERAPEUTICS CORP. | Chief Executive Officer | 02/02/2015 | - |
| Chairman | 02/02/2015 | - | |
| Founder | 02/02/2015 | - | |
| President | 02/02/2015 | - | |
Medicenna Therapeutics, Inc.
 Medicenna Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Medicenna Therapeutics, Inc. develops and commercializes therapeutics for the treatment of central nervous system and urological cancers. It also develops proprietary therapeutic cytokines called Superkines, Superkines is powerful immune-system modulators that have significant therapeutic potential for the treatment of many forms of cancer and selected other diseases. Superkines can be fused to tumor cell-killing payloads to form Medicenna's proprietary Empowered Cytokines (EC's). The firm's EC's are being developed for the targeted treatment of cancer and are potentially vastly superior alternatives to other targeted cancer therapies such as Antibody Drug Conjugates. The company was founded by Fahar Merchan and Rosemina Merchant in 2011 and is headquartered in Vancouver, CA. | Chief Executive Officer | 01/10/2012 | - |
| Chairman | 01/10/2012 | - | |
| Founder | 01/10/2012 | - | |
| President | 01/10/2012 | - |
Storia della carriera di Fahar Merchant
Precedenti posizioni note di Fahar Merchant
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| SOPHIRIS BIO | Chief Executive Officer | 18/04/2005 | 18/04/2011 |
| President | 18/04/2005 | 18/04/2011 | |
| Aries Biologics, Inc. | President | 01/04/2002 | 01/04/2005 |
| KS Biomedix Plc | Director/Board Member | 01/01/2003 | 01/01/2003 |
| Chief Tech/Sci/R&D Officer | 01/06/2001 | 01/01/2003 | |
| KS Avicenna, Inc. | President | 01/06/2001 | 01/06/2002 |
Avicenna Medica, Inc.
 Avicenna Medica, Inc. Electronic Equipment/InstrumentsElectronic Technology Part of Xenova KS Ltd., Avicenna Medica, Inc. develops and provides cytotoxic agent delivery products. The Canadian company was founded by Fahar Merchant. Avicenna Medica was acquired by K.S. Biomedix Holdings Plc on July 13, 2001 for $58.72 million. | Founder | 01/01/2000 | 01/07/2001 |
| Intelligene Expressions, Inc. | Founder | 01/01/1992 | 01/07/2001 |
Formazione di Fahar Merchant
| University of Western Ontario | Doctorate Degree |
| University of Birmingham | Undergraduate Degree |
Statistiche
Distribuzione geografica
| Canada | 8 |
| Regno Unito | 3 |
| 2 |
Posizioni
| President | 5 |
| Founder | 4 |
| Chief Executive Officer | 3 |
Settori
| Health Technology | 3 |
| Consumer Services | 3 |
| Electronic Technology | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Aziende private | 8 |
|---|---|
Sophiris Bio, Inc.
 Sophiris Bio, Inc. Pharmaceuticals: MajorHealth Technology Sophiris Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of products for the treatment of urological diseases. The company was founded by James L. Heppell in May 2003 and is headquartered in La Jolla, CA. | Health Technology |
Avicenna Medica, Inc.
Avicenna Medica, Inc. Electronic Equipment/InstrumentsElectronic Technology Part of Xenova KS Ltd., Avicenna Medica, Inc. develops and provides cytotoxic agent delivery products. The Canadian company was founded by Fahar Merchant. Avicenna Medica was acquired by K.S. Biomedix Holdings Plc on July 13, 2001 for $58.72 million. | Electronic Technology |
| KS Biomedix Plc | |
| Aries Biologics, Inc. | |
| KS Avicenna, Inc. | |
| Intelligene Expressions, Inc. | |
Medicenna Therapeutics, Inc.
Medicenna Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Medicenna Therapeutics, Inc. develops and commercializes therapeutics for the treatment of central nervous system and urological cancers. It also develops proprietary therapeutic cytokines called Superkines, Superkines is powerful immune-system modulators that have significant therapeutic potential for the treatment of many forms of cancer and selected other diseases. Superkines can be fused to tumor cell-killing payloads to form Medicenna's proprietary Empowered Cytokines (EC's). The firm's EC's are being developed for the targeted treatment of cancer and are potentially vastly superior alternatives to other targeted cancer therapies such as Antibody Drug Conjugates. The company was founded by Fahar Merchan and Rosemina Merchant in 2011 and is headquartered in Vancouver, CA. | Health Technology |
| Medicenna Therapeutics Corp. |
- Borsa valori
- Insiders
- Fahar Merchant
- Esperienza
